Locally Advanced or Metastatic CRC
Conditions
Brief summary
This is a phase II clinical study to evaluate the safety and antitumor activity of LTC004 in patients with locally advanced or metastatic CRC，Enrollment of 10 evaluable subjects in Phase I. If ≥2 subjects experience objective remission，proceed to Phase II to enroll an additional 20 evaluable subjects to further evaluation of the safety and efficacy of LTC004
Interventions
DRUGLTC004
LTC004,45μg/kg,IV,Day 1,Q3W;
Sponsors
Letolab
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 18 to 75 years. 2. Non-radical resectable metastatic colorectal cancer confirmed by histology or cytology (pathology report required). 3. Those who have progressed on, or are intolerant to, at least three lines of prior systemic antitumor therapy for metastatic colorectal cancer. Patients must have received fluorouracil, oxaliplatin, and irinotecan-based chemotherapy, as well as patients with mCRC who have received or are not candidates for prior anti-VEGF therapy, TKI agents, and anti-epidermal growth factor receptor therapy (RAS wild-type). 4. At least one measurable tumor lesion based on RECIST V1.1 criteria. 5. ECOG PS ≤1. 6. Expected survival ≥12 weeks. 7. Adequate organ function. 8. Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for 6 months after the last infusion of LTC004. 9. Patients who have received any chemotherapy or anti-tumor monoclonal antibody drugs within 4 weeks prior to the first dose of study drug.small molecule targeted drugs within 2 weeks prior to the first dose of study drug; Chinese medicine therapy (Chinese medicine therapy with clear anti-tumor indications in the package insert within 4 weeks prior to the first dose of study drug. 10. Understands and provides written informed consent and willing to follow the requirements specified in protocol.
Exclusion criteria
1. History of severe hypersensitivity reactions to other mAbs. 2. Untreated, unstable or uncontrolled central nervous system (CNS) metastases with following exceptions:A. Clinically stable MRI scans and no progressive or uncontrolled neurologic symptoms or signs for at least 4 weeks prior to the first study treatment. 3. Tumor invasion of vital arteries resulting in high risk of bleeding, significant risk of perforation or already formed fistulae. 4. Patients with uncontrolled pleural effusion, pericardial effusion or abdominal effusion as judged by the investigator at screening. 5. Patients with untreated or clinically symptomatic spinal cord compression that has not been controlled. 6. Previous antitumor regimens include immunotherapy such as PD-1/L1 inhibitors, LAG3, TIGIT, IL-2, IL-15, CD3-like immunoagonists, and other cellular therapies. 7. ≥2 malignant tumors within 5 years prior to first dose of drug. 8. Moderate to severe dyspnea at rest, severe primary lung disease,current need for continuous oxygen therapy, or clinically active interstitial lung disease (ILD) or pneumonia due to advanced cancer or its complications; Grade ≥3 interstitial pneumonia during prior antineoplastic therapy. 9. Presence of severe infection within 4 weeks prior to first dose of medication.Presence of active infection requiring systemic antibiotic therapy with CTCAE grade ≥2 within 2 weeks prior to first dose. 10. History of serious cardiovascular disease. 11. Active bleeding disorders, including gastrointestinal bleeding, as evidenced by vomiting of blood, profuse hemoptysis, or black stools, have occurred in the 6 months prior to enrollment. 12. Active hepatitis B,hepatitis C infection,syphilis infection, active tuberculosis. 13. Patients with active, or previous autoimmune disease with potential for recurrence. 14. Immunodeficiency diseases or history of such diseases, including a positive serologic test for human immunodeficiency virus (HIV). 15. Arterial/venous thrombotic events within 6 months prior to the first dose of the drug. 16. Those who received radical radiation therapy within 4 weeks prior to the first dose and those who received palliative radiation within 14 days prior to the first dose. 17. Use of live or attenuated vaccines within 4 weeks prior to the first dose,or anticipated need for live or attenuated vaccines during the study period. 18. Major surgery (other than surgery for diagnostic purposes) within 4 weeks prior to the first dose, anticipation of major surgery (other than surgery for diagnostic purposes) during the study period, or diagnostic or low-invasive surgery within 7 days prior to the first dose (excluded for puncture biopsies). 19. Adverse effects of prior antitumor therapy have not recovered to CTCAE version 5.0 grade rating ≤1. 20. Patients who have received a previous allogeneic bone marrow/hematopoietic stem cell transplant or solid organ transplant. 21. Pregnant and lactating women. 22. Subjects who in the judgment of the investigator, have a history of other serious systemic disease or are unfit to participate in this trial for any other reason (the presence of psychiatric disorders in the patient that may affect compliance with the trial, alcohol, drug or substance abuse,etc.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | up to 12 months | Antitumor efficacy of LTC004 treated CRC patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DOR | up to 12 months | Duration of Response of LTC004 treated CRC patients |
| PFS | up to 12 months | Progression-Free Survival of LTC004 treated sarcoma patients |
| OS | up to 12 months | Overall Survival of LTC004 treated CRC patients |
Outcome results
None listed